Applied Clinical Trials
September 01, 2019
Feature Articles
28
9
Executives from across the clinical research enterprise converge to discuss the steps-and technology-needed to strengthen industrywide data sharing.
September 01, 2019
News
28
9
Joel B. Selzer, co-founder and CEO, ArcheMedX, Inc., discusses the impact that healthcare technology has on clinical trials, focusing on the development of the company’s workforce readiness platform.
September 01, 2019
Feature Articles
28
9
Exploring how clinical research sites are redefining their business models to be more flexible, collaborative, and customized.
September 01, 2019
Feature Articles
28
9
After years of siloed focus-and slow study start-ups-the U.S. Veterans Affairs agency embarks on implementing its multi-year initiative to bolster clinical research.
September 01, 2019
News
28
9
The two-year inquiry into possible maladministration at the EMA has intensified.
September 01, 2019
Issue PDF
28
9
Click the title above to open the Applied Clinical Trials September 2019 issue in an interactive PDF format.
September 01, 2019
News
28
9
FDA and other regulators are responding with support for more flexible monitoring of clinical investigators and review of study records in order to limit study monitoring to certain situations.
September 01, 2019
Feature Articles
28
9
Bristol-Myers Squibb’s cardiovascular development leader discusses the importance of diversifying clinical trials for better patient outcomes.
September 01, 2019
From the Editor
28
9
A view of highlights and trends from the September 2019 issue, alongside trends mentioned around site practices during the year.
September 01, 2019
Clinical Trial Insights
28
9
Interest in benchmark data on the scope, performance, and economics of rare disease drug development efforts has grown.
September 01, 2019
News
28
9
A case study of the Parkinson’s Progression Markers Initiative.
September 01, 2019
A Closing Thought
28
9
Organizations that continue to disregard the technological needs of one of the industry’s core audiences run the risk of having their trials ignored.